Seminars in Nephrology
Volume 25, Issue 4 , Pages 198-209 , July 2005

Hypertension Treatment Guidelines: Practical Implications

  • Kenneth L. Choi
    • ,
  • George L. Bakris

      Affiliations

    • Corresponding Author InformationAddress reprint requests to George Bakris, MD, Rush University Medical Center, 1700 W. Van Buren St, Suite 470, Chicago, IL 60612.

References 

  1. Chobanian AV , Bakris GL , Black HR , et al.   Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure . Hypertension . 2003;42:1206–1252
  2. Summary of Revisions for the 2004 Clinical Practice Recommendations . Diabetes Care . 2004;27:S1–S146
  3. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension . J Hypertens . 2003;21:1011–1053
  4. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease . Am J Kidney Dis . 2004;43:1–290
  5. Lewington S , Clarke R , Qizilbash N , et al.   Age-specific relevance of usual blood pressure to vascular mortality (A meta-analysis of individual data for one million adults in 61 prospective studies) . Lancet . 2002;360:1903–1913
  6. UK Prospective Diabetes Study Group . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38) . BMJ . 1998;317:703–713
  7. Hansson L , Zanchetti A , Carruthers SG , et al.  HOT Study Group   Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension (Principal results of the Hypertension Optimal Treatment (HOT) randomised trial) . Lancet . 1998;351:1755–1762
  8. Bakris GL , Williams M , Dworkin L , et al.  National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group   Preserving renal function in adults with hypertension and diabetes (A consensus approach) . Am J Kidney Dis . 2000;36:646–661
  9. Elliott WJ , Weir DR , Black HR  Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure . Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients . Arch Intern Med . 2000;160:1277–1283
  10. Jafar TH , Stark PC , Schmid CH , et al.  AIPRD Group   Progression of chronic kidney disease: The role of blood pressure, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis . Ann Intern Med . 2003;39:244–252
  11. Schrier RW , Estacio RO , Esler A , et al.   Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes . Kidney Int . 2002;61:1086–1097
  12. Wright JT , Bakris G , Greene T , et al.   Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease (Results from the AASK trial) . JAMA . 2002;288:2421–2431
  13. SHEP Cooperative Research Group . Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP) . JAMA . 1991;265:3255–3264
  14. Perry HM , Davis BR , Price TR , et al.   Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke (the Systolic Hypertension in the Elderly Program (SHEP)) . JAMA . 2000;284:465–471
  15. He J , Whelton PK , Appel LJ , et al.   Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension . Hypertension . 2000;35:544–549
  16. Whelton PK , Appel LJ , Espeland MA , et al.  TONE Collaborative Research Group   Sodium reduction and weight loss in the treatment of hypertension in older persons (A randomized controlled trial of nonpharmacologic interventions in the elderly (TONE)) . JAMA . 1998;279:839–846
  17. Appel LJ , Champagne CM , Harsha DW , et al.   Effects of comprehensive lifestyle modification on blood pressure control (Main results of the PREMIER clinical trial) . JAMA . 2003;289:2083–2093
  18. The Trials of Hypertension Prevention Collaborative Research Group . Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II . Arch Intern Med . 1997;157:657–667
  19. Kawano Y , Pontes CS , Abe H , et al.   Effects of alcohol consumption and restriction on home blood pressure in hypertensive patients (Serial changes in the morning and evening records) . Clin Exp Hypertens . 2002;24:33–39
  20. Saito K , Yokoyama T , Yoshiike N , et al.   Do the ethanol metabolizing enzymes modify the relationship between alcohol consumption and blood pressure? . J Hypertens . 2003;21:1097–1105
  21. Appel LJ , Moore TJ , Obarzanek E , et al.  DASH Collaborative Research Group   A clinical trial of the effects of dietary patterns on blood pressure . N Engl J Med . 1997;336:1117–1124
  22. Sacks FM , Svetkey LP , Vollmer WM , et al.  DASH-Sodium Collaborative Research Group   Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet . N Engl J Med . 2001;344:3–10
  23. Minami J , Ishimitsu T , Matsuoka H . Effects of smoking cessation on blood pressure and heart rate variability in habitual smokers . Hypertension . 1999;33:586–590
  24. Bolinder G , de Faire U . Ambulatory 24-h blood pressure monitoring in healthy, middle-aged smokeless tobacco users, smokers, and nontobacco users . Am J Hypertens . 1998;11:1153–1163
  25. Whelton SP , Chin A , Xin X , et al.   Effect of aerobic exercise on blood pressure (A meta-analysis of randomized, controlled trials) . Ann Intern Med . 2002;136:493–503
  26. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic (The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)) . JAMA . 2002;288:2981–2997
  27. ALLHAT Collaborative Research Group . Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone (the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)) . JAMA . 2000;283:1967–1975
  28. Turnbull F . Effects of different blood-pressure-lowering regimens on major cardiovascular events (Results of prospectively-designed overviews of randomised trials) . Lancet . 2003;362:1527–1535
  29. Saunders E , Weir MR , Kong BW , et al.   A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks . Arch Intern Med . 1990;150:1707–1713
  30. Exner DV , Dries DL , Domanski MJ , et al.   Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction . N Engl J Med . 2001;344:1351–1357
  31. Lithell H , Hansson L , Skoog I , et al.   The Study on Cognition and Prognosis in the Elderly (SCOPE) (Principal results of a randomized double-blind intervention trial) . J Hypertens . 2003;21:875–886
  32. Heart Outcomes Prevention Evaluation Study Investigators . Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus (Results of the HOPE study and MICRO-HOPE substudy) . Lancet . 2000;355:253–259
  33. Jamerson KA , Bakris GL , Wun CC , et al.   Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial (The first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension) . Am J Hypertens . 2004;17:793–801
  34. Nishizaka MK , Zaman MA , Green SA , et al.   Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism . Circulation . 2004;109:2857–2861
  35. Calhoun DA , Nishizaka MK , Zaman MA , et al.   Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea . Chest . 2004;125:112–117
  36. Krum H , Nolly H , Workman D , et al.   Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients . Hypertension . 2002;40:117–123
  37. White WB , Carr AA , Krause S , et al.   Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension . Am J Cardiol . 2003;92:38–42
  38. Wachtell K , Ibsen H , Olsen MH , et al.   Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy (The LIFE study) . Ann Intern Med . 2003;139:901–906
  39. De Zeeuw D , Remuzzi G , Parving HH , et al.   Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy . Circulation . 2004;110:921–927
  40. Hillege HL , Fidler V , Diercks GF , et al.   Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population . Circulation . 2002;106:1777–1782
  41. Bakris GL , Weir M . ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes (What’s the evidence) . J Clin Hypertens . 2002;4:420–423
  42. Bakris GL , Weir MR , DeQuattro V , et al.   Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy . Kidney Int . 1998;54:1283–1289
  43. Boero R , Rollino C , Massara C , et al.   The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study . Am J Kidney Dis . 2003;42:67–75
  44. Nakao N , Yoshimura A , Morita H , et al.   Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE) (A randomised controlled trial) . Lancet . 2003;361:117–124
  45. Bakris GL , Weir MR . Salt intake and reductions in arterial pressure and proteinuria . Is there a direct link? Am J Hypertens . 1996;9:200S–206S
  46. Peterson JC , Adler S , Burkart JM , et al.   Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study . Ann Intern Med . 1995;123:754–762
  47. Bakris GL , Weir MR , Shanifar S , et al.   Effects of blood pressure level on progression of diabetic nephropathy (Results from the RENAAL study) . Arch Intern Med . 2003;163:1555–1565
  48. Bakris GL , Weir MR . Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine (Is this a cause for concern?) . Arch Intern Med . 2000;160:685–693
  49. Sato A , Saruta T . Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy . Am J Hypertens . 2003;16:781–788
  50. Sato A , Saruta T . Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy . J Int Med Res . 2001;29:13–21
  51. Hene RJ , Boer P , Koomans HA , et al.   Plasma aldosterone concentrations in chronic renal disease . Kidney Int . 1982;21:98–101
  52. Hollenberg NK . Aldosterone in the development and progression of renal injury . Kidney Int . 2004;66:1–9
  53. Hostetter TH , Ibrahim HN . Aldosterone in chronic kidney and cardiac disease . J Am Soc Nephrol . 2003;14:2395–2401
  54. Sato A , Hayashi K , Naruse M , et al.   Effectiveness of aldosterone blockade in patients with diabetic nephropathy . Hypertension . 2003;41:64–68
  55. Chrysostomou A , Becker G . Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease . N Engl J Med . 2001;345:925–926
  56. Gress TW , Nieto FJ , Shahar E , et al.   Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study . N Engl J Med . 2000;342:905–912
  57. Sowers JR , Bakris GL . Antihypertensive therapy and the risk of type 2 diabetes mellitus . N Engl J Med . 2000;342:969–970
  58. Elisaf MS , Theodorou J , Pappas H , et al.   Effectiveness and metabolic effects of perindopril and diuretics combination in primary hypertension . J Hum Hypertens . 1999;13:787–791
  59. Grimm RH , Flack JM , Grandits GA , et al.  Treatment of Mild Hypertension Study (TOMHS) Research Group   Long-term effects on plasma lipids of diet and drugs to treat hypertension . JAMA . 1996;275:1549–1556
  60. Hansson L , Lindholm LH , Niskanen L , et al.   Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension (The Captopril Prevention Project (CAPPP) randomised trial) . Lancet . 1999;353:611–616
  61. Dahlof B , Devereux RB , Kjeldsen SE , et al.   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) (A randomised trial against atenolol) . Lancet . 2002;359:995–1003
  62. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic (The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)) . JAMA . 2002;288:2981–2997
  63. Julius S , Kjeldsen SE , Weber M , et al.   Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine (The VALUE randomised trial) . Lancet . 2004;363:2022–2031
  64. Brenner BM , Cooper ME , de Zeeuw D , et al.   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy . N Engl J Med . 2001;345:861–869
  65. Lewis EJ , Hunsicker LG , Clarke WR , et al.   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes . N Engl J Med . 2001;345:851–860
  66. Gerstein HC . Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment (HOPE and MICRO-HOPE) . Diabetes Metab Rev . 2002;18(suppl 3):S82–S85
  67. Voyaki SM , Staessen JA , Thijs L , et al.  Systolic Hypertension in Europe (Syst-Eur) Trial Investigators   Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension . J Hypertens . 2001;19:511–519
  68. Koshy S , Bakris GL . Therapeutic approaches to achieve desired blood pressure goals (Focus on calcium channel blockers) . Cardiovasc Drugs Ther . 2000;14:295–301
  69. Bakris GL , Weir MR , Secic M , et al.   Differential effects of calcium antagonist subclasses on markers of nephropathy progression . Kidney Int . 2004;65:1991–2002
  70. Bakris GL , Gaxiola E , Messerli FH , et al.   Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study . Hypertension . 2004;44:1–6
  71. Levy D , Larson MG , Vasan RS , et al.   The progression from hypertension to congestive heart failure . JAMA . 1996;275:1557–1562
  72. Kitzman DW , Little WC , Brubaker PH , et al.   Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure . JAMA . 2002;288:2144–2150
  73. Pfeffer MA , Swedberg K , Granger CB , et al.   Effects of candesartan on mortality and morbidity in patients with chronic heart failure (The CHARM-overall programme) . Lancet . 2003;362:759–766
  74. Psaty BM , Smith NL , Siscovick DS , et al.   Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis . JAMA . 1997;277:739–745
  75. Pitt B , Zannad F , Remme WJ , et al.  Randomized Aldactone Evaluation Study Investigators   The effect of spironolactone on morbidity and mortality in patients with severe heart failure . N Engl J Med . 1999;341:709–717
  76. Pitt B , Williams G , Remme W , et al.   The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study . Cardiovasc Drugs Ther . 2001;15:79–87
  77. Pfeffer MA , McMurray JJ , Velazquez EJ , et al.   Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both . N Engl J Med . 2003;349:1893–1906
  78. Cohn JN , Tognoni G . A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure . N Engl J Med . 2001;345:1667–1675
  79. Yeghiazarians Y , Braunstein JB , Askari A , et al.   Unstable angina pectoris . N Engl J Med . 2000;342:101–114
  80. Heidenreich PA , McDonald KM , Hastie T , et al.   Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina . JAMA . 1999;281:1927–1936
  81. Fox KM . Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease (Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)) . Lancet . 2003;362:782–788
  82. Pepine CJ , Handberg EM , Cooper-DeHoff RM , et al.   A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial . JAMA . 2003;290:2805–2816
  83. Manjunath G , Tighiouart H , Coresh J , et al.   Level of kidney function as a risk factor for cardiovascular outcomes in the elderly . Kidney Int . 2003;63:1121–1129
  84. Wright RS , Reeder GS , Herzog CA , et al.   Acute myocardial infarction and renal dysfunction (A high-risk combination) . Ann Intern Med . 2002;137:563–570
  85. Trespalacios FC , Taylor AJ , Agodoa LY , et al.   Incident acute coronary syndromes in chronic dialysis patients in the United States . Kidney Int . 2002;62:1799–1805
  86. Conlin PR , Gerth WC , Fox J , et al.   Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes . Clin Ther . 2001;23:1999–2010

PII: S0270-9295(05)00029-X

doi: 10.1016/j.semnephrol.2005.02.004

Seminars in Nephrology
Volume 25, Issue 4 , Pages 198-209 , July 2005

Article Tools

* Image Usage & Resolution